Featured Platforms

Custom Protein Generation

Mammalian- Derived Products

Microbial- Derived Products

Antibody Drug Conjugates

Bispecific Ab Platform

Technologies & Platforms

WuXi Biologics is committed to providing open-access technology platforms so that any company anywhere can efficiently and cost effectively bring new medicines to patients worldwide. Our technology platforms span the entire discovery to manufacturing spectrum.


WuXi Biologics offers five advanced platforms for discovery of antibody-based therapeutics and we leverage these platforms individually or combined to find the ideal therapeutic antibody.

  1. Advanced Hybridoma System

  2. Phage Display

  3. OMT Technology

  4. WuXiBody™ Bispecific Antibody Platform

  5. Antibody Drug Conjugates

Learn more


CRISPR/Cas9 Gene Editing Services

WuXi Biologics has taken a research license of CRISPR/Cas9 technologies from the Broad Institute for use in biologics and vaccine research and development. The applications for CRISPR gene editing are vast and can be applied to producer cell lines or other protein expression systems to improve cell growth, productivity, product titer and product quality.  Let our team of experts help you determine if the use of CRISPR is right for your product and project needs.

Learn more


WuXiBody™ Bispecific Antibody Platform

WuXiBody™ is an innovative, proprietary technology platform developed by WuXi Biologics for the expanding field of bispecific antibodies. Based on novel engineering, the platform can expedite the drug development process by 6-18 months and significantly reduce cost-of-goods.  The WuXiBody™ platform enables almost any mAb sequence pair to be assembled into the bispecific construct and its unique structural flexibility makes the platform convenient to build various formats with different valency (e.g., 2, 3 or 4 binding sites).

Learn more


WuXian Express for Custom Protein Production

Our unique Wuxian Express custom protein production platform for generation of R&D-grade proteins and antibodies is designed to fill the gap between transient production and traditional stable pool methodologies. Compared to transient production, Wuxian Express delivers significantly more material, yet only adds 1 week to the overall timeline. Compared to the traditional stable pool production, Wuxian Express is 6 weeks faster and thus offers significant time and cost savings to obtain the same production scale.

Learn more


WuXia Cell Line Development

Our proprietary CHO K1 cell line development platform was designed to provide high titer production cell lines while also keeping drug development costs low and allows ultimate flexibility for cell line use in the production of protein therapeutics. Product titers as high as 10 g/L can be achieved with this system.

Learn more


WuXiUP Continuous Process Platform

The breakthrough WuXiUP process couples continuous perfusion cell culture with continuous direct product capture column chromatography. This highly efficient system enables a similar purification yield to traditional purification processes. With this technology, a 1,000 L disposable bioreactor can produce more than 30 kg of mAb per batch and approximately 500 kg per year, thus providing similar productivity as traditional 10,000-20,000 L stainless steel bioreactors. This process platform can expedite product development and significantly reduce the cost of goods for a commercial product.

Learn more


Scale-Out Manufacturing

Taking advantage of the advancements in disposable manufacturing technologies and in response to market demands for commercial manufacturing operations that reduce risk, costs and offer greater flexibility and scalability for product supply, WuXi Biologics designed and built multiple state-of-the-art manufacturing facilities for clinical and commercial supply of biological therapeutics.

Learn more


Cell Culture Development and Manufacturing

WuXi Biologics utilizes several cell culture technologies that can be used as a standard platform process or customized to meet your protein production requirements. Process platforms include our fed-batch scale-out manufacturing paradigm using single-use disposable bioreactors (up to 4,000 L) and our state-of-the-art WuXiUP continuous biomanufacturing platform with ultra-high productivity.

Learn more


Over 150 different cell-based functional/potency assays have been developed (including 40+ qualified for GMP) by our 70+ team of bioassay experts including our patent pending ADCC and CDC assays.

Learn more


Drug Product Fill & Finish

WuXi Biologics provides parental drug product fill & finish into multiple container and closure configurations utilizing state-of-the-art filling systems that include fully robotic, gloveless, isolator-based fill units capable of performing fills in Ready-To-Use (RTU) container closure systems (CCS).

Learn more